A Once-Failed Pain Therapy Shows Potential in a Neurodevelopmental Disorder

Bruce Leuchter, president and CEO of GRIN Therapeutics, discusses GRIN-related disorders, how the company came to develop radiprodil, and how it represents an effort by Neurvati Neurosciences to bring a portfolio approach to developing novel treatments for neurological and psychiatric disorders.